CytRx's RXi Business Exclusively Licenses Invitrogen's RNAi IP for Rx Apps | GenomeWeb
NEW YORK (GenomeWeb News) — CytRx subsidiary RXi Pharmaceuticals will exclusively license Invitrogen’s second-generation RNAi technology for “designated target genes in all human therapeutic categories,” the companies said today.
 
The intellectual property covers Invitrogen’s Stealth technology and other tools related to chemically modified double-stranded RNA.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.